PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis study tests a drug called PLX038 in people with ovarian, fallopian tube, or peritoneal cancer that has spread and no longer responds to platinum chemotherapy. The goal is to see if PLX038 can shrink tumors. About 43 adults with advanced cancer will receive the drug, and rese…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Supercharged immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The ma…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could a pneumonia drug outsmart resistant ovarian cancer?
Disease control Recruiting nowThis study tests whether atovaquone, a drug normally used for infections, can help people with a type of ovarian cancer that no longer responds to standard platinum chemotherapy. About 28 adults with this resistant cancer will take atovaquone to see if it slows tumor growth. The …
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 05, 2026 11:54 UTC